Vidarbha News

Extensive R&D activities of pharmaceutical companies such as Ixaka, Hemostemix, and others will significantly impact the Critical Limb Ischemia market size

 Breaking News
  • No posts were found

Extensive R&D activities of pharmaceutical companies such as Ixaka, Hemostemix, and others will significantly impact the Critical Limb Ischemia market size

August 06
17:38 2021
Extensive R&D activities of pharmaceutical companies such as Ixaka, Hemostemix, and others will significantly impact the Critical Limb Ischemia market size
Critical Limb Ischemia Market
The launch of pipeline therapies such as REX-001, ACP-01, and others are anticipated to provide a major push to the growth of the Critical Limb Ischemia market size in the forecast period 2021-30 in the 7MM.

DelveInsight’s Critical Limb Ischemiamarket report provides an in-depth understanding of Critical Limb Ischemia, historical and forecasted epidemiology, and Critical Limb Ischemia market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also discusses current Critical Limb Ischemia treatment practices/algorithms, Critical Limb Ischemia market drivers, Critical Limb Ischemia market barriers, and unmet medical needs.

Some of the Key Highlights from the Critical Limb Ischemia Market Report

  • According to a study conducted by Fereydooni et al. (2020), there are 6.5 million patients with Critical Limb Ischemia in the United States, Europe, and Japan, based on global population-based studies.

  • As per DelveInsight analysis, Critical Limb Ischemia is more common in males as compared to females.

  • Key pharmaceutical players such as Ixaka Ltd., Hemostemix, Caladrius Biosciences, Inc., BioGenCell Ltd., and others are diligently working towards the development of novel therapies for Critical Limb Ischemia treatment.

  • Ixaka Ltd. is developing REX-001, which is currently in Phase III of development to treat ischemic ulcers in subjects with Critical Limb Ischemia.

  • A very few late-stage therapies for Critical Limb Ischemia are being investigated in ongoing industrial clinical trials. The therapies which are in Phase II of development include ACP-01, CLBS12, along with others.

Request for sample for better understanding about the signs of critical limb ischemia @ Management of Critical Limb Ischemia

The Critical Limb Ischemia market report also covers current treatment practices, emerging drugs, Critical Limb Ischemia market share of individual therapies, as well as current and forecasted Critical Limb Ischemia market Size from 2018 to 2030, segmented by seven major markets.

Critical Limb Ischemia: Overview

Critical Limb Ischemia is a severe artery occlusion that causes extreme pain and even skin ulcers or sores in the extremities (hands, feet, and legs). The discomfort caused by Critical Limb Ischemia may keep a person awake at night. This pain, commonly referred to as “rest pain,” usually occurs in the leg and can be temporarily relieved by hanging the leg over the edge of the bed or getting up to walk around.

Critical Limb Ischemia Epidemiology Segmentation

The Critical Limb Ischemia report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Critical Limb Ischemia Prevalent Cases

  • Critical Limb Ischemia Gender-Specific Prevalent Cases

  • Critical Limb Ischemia Age-Specific Prevalent Cases 

  • Critical Limb Ischemia Grade-Specific Prevalent Cases 

  • Critical Limb Ischemia Diagnosed and Treatable Cases 

Critical Limb Ischemia Treatment Landscape

Critical limb ischemia is a potentially fatal condition that necessitates immediate medical attention in order to restore blood flow to the affected area or areas. The sooner a diagnosis is made, the sooner treatment can begin with less serious consequences. The major options for Critical Limb Ischemia treatment include:

  • Medications

  • Endovascular Treatments

  • Arterial Surgery

  • Regenerative and Adjunctive Therapies

Get a detailed analysis of the upcoming critical limb ischemia treatment options @ Critical Limb Ischemia Treatment Market 

Critical Limb Ischemia Market 

The launch of pipeline therapies such as REX-001, ACP-01, CLBS12, and others by key pharmaceutical companies such as Ixaka Ltd., Hemostemix, Caladrius Biosciences, Inc., and several others is anticipated to provide a major push to the growth of the Critical Limb Ischemia market size in the forecast period 2021-30 in the 7MM. 

Critical Limb Ischemia Pipeline Therapies and Key Companies 

  • REX-001: Ixaka Ltd.

  • ACP-01: Hemostemix 

  • CLBS12: Caladrius Biosciences, Inc.

  • BGC101: BioGenCell Ltd.

Table of Contents 

1.

Report Introduction

2.

Critical Limb Ischemia Market Share at a glance

3.

Critical Limb Ischemia Disease Background and Overview

4.

Critical Limb Ischemia Epidemiology and Patient Population

5.

Country Wise: Epidemiology of Critical Limb Ischemia

6.

Critical Limb Ischemia Current Treatment & Medical Practices

7.

Critical Limb Ischemia Marketed Drugs

8.

Critical Limb Ischemia Emerging Drugs

9.

Critical Limb Ischemia Market Size

10.

Region-Wise Market size of Critical Limb Ischemia (2018-2030)

11.

Critical Limb Ischemia Market Drivers

12.

Critical Limb Ischemia Market Barriers

13.

Future Perspectives & Conclusion

14.

Analyst View

15.

Appendix

16.

Report Methodology

17.

DelveInsight Capabilities

18.

Disclaimer

19.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Acute Ischemic Stroke Market 

Get comprehensive historical and forecast analysis of Acute Ischemic Stroke Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Pfizer Inc., Biogen, Merck & Co., Inc., Penumbra, Inc., Genentech, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/